Key facts
- This page summarizes Robert Alexander Ingram's Form 4 filing for BIOCRYST PHARMACEUTICALS INC (BCRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Mar 2023, 15:41.
Robert Alexander Ingram - 28 Feb 2023 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)
- Reporting relationship
- Director
- Issuer ticker
- BCRX
- Reported as of
- 28 Feb 2023
- Net transaction value
- +$19,992
- SEC form
- 4
- Accepted by SEC
- 02 Mar 2023, 15:41:35 UTC
- Prior SEC filing
- 19 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alane P. Barnes, by power of attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert Alexander Ingram filed Form 4 for BIOCRYST PHARMACEUTICALS INC (BCRX) on 02 Mar 2023.
Change
- Previous filing in this sequence was filed on 19 Dec 2022.
- Current net transaction value: +$19,992.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCRX
transaction
Common Stock
Award
- Transaction value
- $19,992
- Shares
- +2,259
- Change %
- +2.3%
- Price
- $8.85
- Shares after
- 100,198
- Date
- 28 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $20,000.